Alignment Healthcare (NASDAQ:ALHC) has received mixed analyst ratings over the last three months, with a shift towards a more bearish stance in the last 30 days. The average 12-month price target for ALHC has increased to $9.25 from $8.88. Analysts from firms like Barclays, UBS, Stifel, Raymond James, and Stephens & Co. have adjusted their ratings and price targets, reflecting changes in market conditions and company performance. Alignment Healthcare, a provider of Medicare Advantage plans, has shown impressive revenue growth of 28.63% as of December 31, 2023, but struggles with profitability and efficient asset utilization, as indicated by its net margin, ROE, and ROA.